Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{ce2aa25e24c140eb8916521f7972f52b,
title = "The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression",
abstract = "Background and purpose: The influence of glucocorticoid induced hyperglycemia on survival in patients with metastatic spinal cord compression (MSCC) is unknown.Materials and methods: In a prospective, observational cohort study 131 patients with MSCC referred to radiotherapy, 30 Gray (Gy) in 10 fractions, and treated with ≥100 mg prednisolone a day were followed with daily blood glucose measurements during radiotherapy.Results: During follow-up a total of 56 patients 43% (95% CI = 35-52%) presented plasma glucose values diagnostic of diabetes. Sixteen patients who developed diabetes were treated with insulin, 12% (95% CI = [6%; 18%]) of the total population. The patients developing diabetes with need for insulin therapy during glucocorticoid therapy had a significantly increased mortality compared to those with normal glucose metabolism and with diabetes without need for therapy, hazard ratio = 2.1 (95% CI = 1.08-4.09, p = 0.0285).Discussion: To our knowledge this is the first prospective study to describe the influence of glucocorticoid induced diabetes on survival in patients with MSCC from different primary tumors.Conclusions: The results indicate that development of diabetes during high-dose glucocorticoid therapy needing insulin treatment in patients with MSCC from different primary tumors is associated with reduced survival.",
author = "Helga Schultz and Ulrik Pedersen-Bjergaard and Jensen, {Andreas Kryger} and Engelholm, {Svend Aage} and Kristensen, {Peter Lommer}",
year = "2018",
doi = "10.1016/j.ctro.2018.04.004",
language = "English",
volume = "11",
pages = "19--25",
journal = "Clinical and Translational Radiation Oncology",
issn = "2405-6308",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

AU - Schultz, Helga

AU - Pedersen-Bjergaard, Ulrik

AU - Jensen, Andreas Kryger

AU - Engelholm, Svend Aage

AU - Kristensen, Peter Lommer

PY - 2018

Y1 - 2018

N2 - Background and purpose: The influence of glucocorticoid induced hyperglycemia on survival in patients with metastatic spinal cord compression (MSCC) is unknown.Materials and methods: In a prospective, observational cohort study 131 patients with MSCC referred to radiotherapy, 30 Gray (Gy) in 10 fractions, and treated with ≥100 mg prednisolone a day were followed with daily blood glucose measurements during radiotherapy.Results: During follow-up a total of 56 patients 43% (95% CI = 35-52%) presented plasma glucose values diagnostic of diabetes. Sixteen patients who developed diabetes were treated with insulin, 12% (95% CI = [6%; 18%]) of the total population. The patients developing diabetes with need for insulin therapy during glucocorticoid therapy had a significantly increased mortality compared to those with normal glucose metabolism and with diabetes without need for therapy, hazard ratio = 2.1 (95% CI = 1.08-4.09, p = 0.0285).Discussion: To our knowledge this is the first prospective study to describe the influence of glucocorticoid induced diabetes on survival in patients with MSCC from different primary tumors.Conclusions: The results indicate that development of diabetes during high-dose glucocorticoid therapy needing insulin treatment in patients with MSCC from different primary tumors is associated with reduced survival.

AB - Background and purpose: The influence of glucocorticoid induced hyperglycemia on survival in patients with metastatic spinal cord compression (MSCC) is unknown.Materials and methods: In a prospective, observational cohort study 131 patients with MSCC referred to radiotherapy, 30 Gray (Gy) in 10 fractions, and treated with ≥100 mg prednisolone a day were followed with daily blood glucose measurements during radiotherapy.Results: During follow-up a total of 56 patients 43% (95% CI = 35-52%) presented plasma glucose values diagnostic of diabetes. Sixteen patients who developed diabetes were treated with insulin, 12% (95% CI = [6%; 18%]) of the total population. The patients developing diabetes with need for insulin therapy during glucocorticoid therapy had a significantly increased mortality compared to those with normal glucose metabolism and with diabetes without need for therapy, hazard ratio = 2.1 (95% CI = 1.08-4.09, p = 0.0285).Discussion: To our knowledge this is the first prospective study to describe the influence of glucocorticoid induced diabetes on survival in patients with MSCC from different primary tumors.Conclusions: The results indicate that development of diabetes during high-dose glucocorticoid therapy needing insulin treatment in patients with MSCC from different primary tumors is associated with reduced survival.

U2 - 10.1016/j.ctro.2018.04.004

DO - 10.1016/j.ctro.2018.04.004

M3 - Journal article

C2 - 30014043

VL - 11

SP - 19

EP - 25

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

SN - 2405-6308

ER -

ID: 54881976